Lonza : Lonza has improved its strategic position in biologics and is expected to benefit from political tailwinds
>Lonza’s equity story has become more attractive since our initiation - Since we initiated the coverage of Lonza on 5 March 2024, several aspects of the equity story have further improved. The appointment of Wolfgang Wienand as CEO in April has ended a period of uncertainty regarding the company's future leadership. Even more importantly, Lonza's strategic position has improved with the acquisition of Genentech in the US. This is particularly true regarding the expect...Lonza supplies services and products that range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions. Co. operates in two segments: Lonza Pharma & Biotech, which clusters all of Co.'s offerings for pharmaceutical markets, focuses on providing custom development, custom manufacturing, cell therapy, viral therapeutics and bioscience solutions; and Lonza Specialty Ingredients, which includes offerings in its consumer care, agro ingredients, industrial solutions, wood protection and water treatment.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.